January 26, 2018 / 10:37 PM / in 20 minutes BRIEF-Celgene Says Entered Into Settlement With Actavis​ Reuters Staff 1 Min Read 
Jan 26 (Reuters) - Celgene Corp: 
* CELGENE - ENTERED INTO SETTLEMENT WITH ACTAVIS LLC TO TERMINATE PENDING PATENT LITIGATION, IPR CHALLENGES RELATING TO CERTAIN PATENTS FOR ABRAXANE​ 
* CELGENE - TO GIVE ACTAVIS LICENSE TO PATENTS TO MANUFACTURE, SELL GENERIC PACLITAXEL PROTEIN-BOUND PARTICLES IN U.S. FROM MARCH 31, 2022 Source text - bit.ly/2EcZicz Further company coverage: